|
||||
|
Published by : PROFESSIONAL MEDICAL PUBLICATIONS |
||||
|
ISSN 1681-715X |
||||
|
||||
|
- |
||||
|
ORIGINAL ARTICLE |
||||
|
- |
||||
|
Volume 26 |
April - June 2010 |
Number 2 |
||
|
|
||||
|
|
||||
|
||||
|
Published by : PROFESSIONAL MEDICAL PUBLICATIONS |
||||
|
ISSN 1681-715X |
||||
|
||||
|
- |
||||
|
ORIGINAL ARTICLE |
||||
|
- |
||||
|
Volume 26 |
April - June 2010 |
Number 2 |
||
|
|
||||
|
|
||||
Phorbol myristate acetate (PMA) induced megakaryocytic
differentiation of K562 cells from human
chronic myelogenous leukaemia patientMuhammad Imran Naseer1, Hassan Zubair2, Ikramullah3,
Najeebullah4, Hae Young Lee5, Myeong Ok Kim6ABSTRACT
Objective: To observe the K562 cell line derived from a patient of chronic myelogenous leukemia differentiated into megakaryocytes by growing in the presence of phorbol myristate acetate (PMA).
Methodology: The differentiation process of K562 cells was monitored by the expression of a platelet cell marker, CD61 through immunocytochemistry using mouse alkaline phosphatase antialkaline phosphatase (APAAP) complex employing fast red TR as substrate, crystal violet and MTT assay used for cell growth analysis.
Results: The crystal in the presence of PMA, cells obtained were of large size and less in number as compared to cells incubated without PMA where they were of smaller size and more in number and immunochemical reaction used to detect the presence of CD61, a platelet cell marker that is expressed during differentiation of K562 cells to megakaryocytes.
Conclusion: The results showed that the addition of PMA to the growing culture of K562 cell lines induced differentiation, observed through CD61 expression and increase in cell size and cessation of proliferation.
KEY WORDS:
PMA, Megakaryocytic, K562 cells, Myelogenous Leukaemia.Pak J Med Sci April - June 2010 Vol. 26 No. 2 352-357
How to cite this article:
Naseer MI, Zubair H, Ikramullah, Najeebullah, Lee HY, Kim MO. Phorbol myristate acetate (PMA) induced megakaryocytic differentiation of K562 cells from human chronic myelogenous leukaemia patient. Pak J Med Sci 2010;26(2):352-357.
1. Muhammad Imran Naseer, PhD,
2. Hassan Zubair, MS
Aberystwyth,
United Kingdom.
3. Ikramullah, PhD
4. Najeebullah, PhD
5. Hae Young Lee, PhD
6. Myeong ok Kim, PhD
1,3-5: Gyeongsang National University,
Chinju 660-701,
South Korea.Correspondence:
Prof. Myeong Ok Kim, PhD
Division of Life Science,
College of Natural Science & Research Institute
of Natural Science, Gyeongsang National University
900 Gazwa 351-301,
Chinju 660-701,
South Korea.
E-mail: mokim@gsnu.ac.kr mimrannaseer@yahoo.com
* Received for Publication: December 2, 2009
* Revision Received: January 19, 2010
* Revision Accepted: January 31, 2010
HOME | SEARCH | CURRENT ISSUE | PAST ISSUES
Professional
Medical Publications
Room No. 522, 5th Floor, Panorama Centre
Building No. 2, P.O. Box 8766, Saddar, Karachi - Pakistan.
Phones : 5688791, 5689285 Fax : 5689860
pjms@pjms.com.pk
